231.97
price up icon2.29%   +5.19
 
loading
Becton Dickinson & Co. stock is currently priced at $231.97, with a 24-hour trading volume of 4.56M. It has seen a +2.29% increased in the last 24 hours and a -1.12% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $225.9 pivot point. If it approaches the $230.8 resistance level, significant changes may occur.
Previous Close:
$226.78
Open:
$227.21
24h Volume:
4.56M
Market Cap:
$67.04B
Revenue:
$19.72B
Net Income/Loss:
$1.33B
P/E Ratio:
42.10
EPS:
5.51
Net Cash Flow:
$3.03B
1W Performance:
+1.39%
1M Performance:
-1.12%
6M Performance:
-1.78%
1Y Performance:
-4.05%
1D Range:
Value
$226.32
$232.21
52W Range:
Value
$224.00
$287.32

Becton Dickinson & Co. Stock (BDX) Company Profile

Name
Name
Becton Dickinson & Co.
Name
Phone
201 847 6800
Name
Address
1 Becton Drive, Franklin Lakes
Name
Employee
65,000
Name
Twitter
@BDandCo
Name
Next Earnings Date
2024-05-14
Name
Latest SEC Filings
Name
BDX's Discussions on Twitter

Becton Dickinson & Co. Stock (BDX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-24-23 Upgrade Raymond James Mkt Perform → Outperform
May-30-23 Resumed Morgan Stanley Overweight
May-05-23 Upgrade Piper Sandler Neutral → Overweight
Apr-12-23 Upgrade KeyBanc Capital Markets Sector Weight → Overweight
Jan-03-23 Upgrade BofA Securities Neutral → Buy
Dec-12-22 Upgrade Citigroup Sell → Neutral
Jul-11-22 Downgrade Citigroup Neutral → Sell
Jun-24-22 Upgrade Wells Fargo Equal Weight → Overweight
Mar-18-22 Resumed Raymond James Mkt Perform
Mar-02-22 Resumed BofA Securities Neutral
Dec-08-21 Downgrade Piper Sandler Overweight → Neutral
Aug-06-21 Downgrade JP Morgan Overweight → Neutral
May-25-21 Initiated Barclays Equal Weight
Dec-15-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-15-20 Downgrade Wells Fargo Overweight → Equal Weight
Jul-09-20 Upgrade Barclays Equal Weight → Overweight
Jun-01-20 Resumed Goldman Buy
Mar-05-20 Initiated Citigroup Neutral
Feb-07-20 Downgrade Cowen Outperform → Market Perform
Feb-07-20 Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Feb-07-20 Downgrade Raymond James Strong Buy → Outperform
Feb-06-20 Downgrade Cowen Outperform → Market Perform
Jan-08-20 Downgrade Barclays Overweight → Equal Weight
May-13-19 Upgrade Barclays Equal Weight → Overweight
Dec-07-18 Initiated Deutsche Bank Buy
Oct-16-18 Initiated Barclays Equal Weight
Jun-21-18 Upgrade JP Morgan Neutral → Overweight
Apr-10-18 Upgrade Citigroup Neutral → Buy
Jan-19-18 Resumed BofA/Merrill Buy
Jan-05-18 Upgrade Citigroup Sell → Neutral
Jan-05-18 Initiated KeyBanc Capital Mkts Overweight
Jan-03-18 Initiated Evercore ISI Outperform
Dec-29-17 Reiterated Deutsche Bank Buy
View All

Becton Dickinson & Co. Stock (BDX) Financials Data

Becton Dickinson & Co. (BDX) Revenue 2024

BDX reported a revenue (TTM) of $19.72 billion for the quarter ending March 31, 2024, a +4.82% rise year-over-year.
loading

Becton Dickinson & Co. (BDX) Net Income 2024

BDX net income (TTM) was $1.33 billion for the quarter ending March 31, 2024, a -17.56% decrease year-over-year.
loading

Becton Dickinson & Co. (BDX) Cash Flow 2024

BDX recorded a free cash flow (TTM) of $3.03 billion for the quarter ending March 31, 2024, a +164.74% increase year-over-year.
loading

Becton Dickinson & Co. (BDX) Earnings per Share 2024

BDX earnings per share (TTM) was $4.54 for the quarter ending March 31, 2024, a -14.82% decline year-over-year.
loading

Becton Dickinson & Co. Stock (BDX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Goette Roland
EVP and President EMEA
May 15 '24
Sale
236.73
3,300
781,224
11,308
Goette Roland
EVP and President EMEA
May 13 '24
Sale
236.70
3,300
781,121
14,608
Garrison Michael David
EVP & President Medical
Apr 30 '24
Sale
232.81
1,715
399,269
5,381
Spoerel Thomas J
SVP,Controller&Chief Acct Off
Mar 14 '24
Sale
238.29
282
67,198
2,276
Garrison Michael David
EVP & President Medical
Dec 11 '23
Sale
232.46
1,239
288,018
7,274
Byrd Richard
EVP & President Interventional
Nov 28 '23
Sale
238.47
2,156
514,141
4,120
Goette Roland
EVP and President, EMEA
Nov 16 '23
Option Exercise
107.12
3,544
379,633
17,164
Byrd Richard
EVP & President Interventional
Sep 05 '23
Sale
274.48
459
125,986
3,444
Fraser Claire
Director
Aug 28 '23
Sale
281.66
848
238,848
21,608
Hickey David
EVP & President, Life Sciences
Aug 11 '23
Option Exercise
132.54
3,883
514,653
9,030
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. It has a strategic partnership with the Biomedical Advanced Research and Development Authority to develop new manufacturing lines for injection devices. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
medical_instruments_supplies ALC
$89.13
price up icon 0.88%
medical_instruments_supplies RMD
$206.33
price down icon 1.44%
medical_instruments_supplies WST
$331.41
price up icon 0.70%
medical_instruments_supplies COO
$94.31
price up icon 4.52%
medical_instruments_supplies BAX
$34.09
price up icon 1.97%
Cap:     |  Volume (24h):